Skip to navigation Skip to content

Severe growth failure with primary insulin-like growth factor-1 deficiency (IGFD) program in Pharmaceutical Benefits Scheme (PBS) 012-22092336

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised mecasermin for patients with severe growth failure with primary insulin-like growth factor-1 deficiency (IGFD).

Severe growth failure with primary IGFD and listing dates

Severe growth failure with primary IGFD is a genetic disease in patients causing short stature and slow growth.

Listing dates:

  • mecasermin - 1 October 2022

See Written Authority Required Drugs for more information.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex Drugs Programs team and choose the option relevant to the condition treated.

The Resources page contains:

  • application forms
  • contact details
  • item and restriction codes
  • the PBS schedule, and
  • Services Australia website link

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Processing written authority approval requests

Written Authority Required Drugs